Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymogen is a synthetic dipeptide consisting of L-glutamyl-L-tryptophan, developed by the St. Petersburg Institute of Bioregulation and Gerontology. It acts as an immunomodulator that normalizes cellular immunity by regulating the count and functional activity of T-lymphocytes. Thymogen is primarily indicated for the treatment and prevention of secondary immunodeficiencies associated with chronic infectious and inflammatory diseases, trauma, surgery, and the side effects of chemotherapy or radiotherapy. It is available in several formulations, including an intranasal spray, an injectable solution, and a topical cream, and has been used in Russia and CIS countries for various conditions including respiratory infections and dermatological disorders like atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymogen.